Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 27;93(8):813-21.
doi: 10.1097/TP.0b013e318247a717.

Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation

Affiliations

Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation

Camila Macedo et al. Transplantation. .

Abstract

Background: Induction with lymphocyte-depleting antibodies is routinely used to prevent rejection but often skews T cells toward memory. It is not fully understood which memory and regulatory T-cell subsets are most affected and how they relate to clinical outcomes.

Methods: We analyzed T cells from 57 living-donor renal transplant recipients (12 reactive and 45 quiescent) 2.8±1.4 years after alemtuzumab induction. Thirty-four healthy subjects and nine patients with acute cellular rejection (ACR) were also studied.

Results: We found that alemtuzumab caused protracted CD4 more than CD8 T-lymphocyte deficiency, increased proportion of CD4 memory T cells, and decreased proportion of CD4 regulatory T cells. Reactive patients exhibited higher proportions of CD4 effector memory T cells (TEM) and CD8 terminally differentiated TEM (TEMRA), with greater CD4 TEM and CD8 TEMRA to regulatory T cell ratios, than quiescent patients or healthy controls. Patients with ongoing ACR had profound reduction in circulating CD8 TEMRA. Mixed lymphocyte assays showed significantly lower T-cell proliferation to donor than third-party antigens in the quiescent group, while reactive and ACR patients exhibited increased effector molecules in CD8 T cells.

Conclusions: Our findings provide evidence that T-cell skewing toward TEM may be associated with antigraft reactivity long after lymphodepletion. Further testing of TEM and TEMRA subsets as rejection predictors is warranted.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1. Identification and quantitation of peripheral blood T cell subsets
Proportion (%) and absolute numbers of CD3+ (A), CD3+CD4+ (B), and CD3+CD8+ (C) T cells in each study group. (D) Gating strategy for identifying TN (CD45ROCD62L+), TCM (CD45RO+CD62L+), TEM (CD45RO+CD62L), and TEMRA (CD45ROCD62L) CD4 and CD8 T cells. (E–F) Proportion (%) of CD4+ TN, TEM, and CD8+ TN, TEMRA cells for each study group. Each symbol represents a single subject, while the horizontal line reprsents the mean value. *p<0.05; ** p<0.01; *** p<0.005.
Figure 2
Figure 2. Identification and quantitation of peripheral blood CD4 TREG and TEFF cells
(A) Gating strategy and representative flow cytometry of TREG (CD3+CD4+CD25highFOXP3+CD127low) and TEFF (CD3+CD4+CD25highFOXP3CD127high) in the CD3+CD4+CD25high T cell gate in each of the study groups. (B) Proportion (%) of TREG and of TEFF within the CD3+CD4+CD25high T cell gate. (C) CD4 TEM/TREG and CD8 TEMRA/TREG ratios in each of the study groups. Each symbol represents a single individual, and the horizontal line represents the mean value. *p<0.05; ** p<0.01; *** p<0.005.
Figure 3
Figure 3. T cell proliferation and IFNγ and peforin/granzyme B expression in one-way CFSE-MLR
Analyses were performed after excluding PKH-26+ stimulator cells and gating on CD3+CD8 (CD4+) and CD3+CD8+ T cells at the end of the 5-day MLR. (A) Proliferation of responder CD4+ and CD8+ T cells, presented as proportion (%) of cells that diluted CFSE, after stimulation with allogeneic donor (R+D) or third party PBMC (R+3rd). (B) IFNγ production by proliferated CD4+ and CD8+ T cells 4 hrs after re-stimulation with donor or third party CD3-depleted allogeneic PBMC. (C) Perforin/granzyme B expression by proliferated responder CD4+ and CD8+ T cells. HC (n=14), quiescent (n=12), reactive (n=4), and ACR (n=2). *p<0.05; ** p<0.01; ***p<0.005.
Figure 4
Figure 4. Identification of T cell subsets in renal allograft tissue of a patient undergoing ACR
(A) H&E staining shows irregularly shaped tubules and mononuclear cell infiltrates (tubulitis) (yellow arrows). (B and C) Multiplex quantum dot staining of CD45RO (green), CD62L (red), CD8 (cyan), and CD3 (yellow) in the same tissue section as A. Panel B depicts merged image, red arrows indicate infiltrating cells which are mostly CD8+CD3+CD45RO+CD62L T cells (TE or TEM). Panel C depicts cropped images from Panel B. White arrow heads indicate tubules. Purple arrows identify CD3+CD8CD45ROCD62L (TEMRA) while white arrows identify CD3+CD8+CD45RO+CD62L (TEM) infiltrating T cells.

Similar articles

Cited by

References

    1. Cai J, Terasaki PI. Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data. Transplantation. 2010;90:1511. - PubMed
    1. Meier-Kriesche H-U, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6 (5 Pt 2):1111. - PubMed
    1. Kirk AD. Induction immunosuppression. Transplantation. 2006;82 (5):593. - PubMed
    1. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant. 2008;8 (7):1480. - PubMed
    1. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am J Transplant. 2006;6 (2):331. - PubMed

Publication types

MeSH terms